Multinational drug giants go for dual in Korean pharmaceutical market

This year, competition is about to heat up in the Korean pharmaceutical market as a growing number of new products would be launched by foreign drug makers.

GSK is about to set foot in the market with its newly developed anti-diabetic drug, named Avandaryl (rosiglitazone maleate and glimepiride), a new fixed-dose combination product for type 2 diabetes, raising the prospects of tougher compe...